Our lab is focused on understanding the ways bacteria resist antibiotics as well as the host immune system during infection. We primarily study the highly antibiotic-resistant Gram-negative bacteria Acinetobacter baumannii, Klebsiella pneumoniae, and Enterobacter cloacae, aiming to identify novel therapeutics to prevent disease.
Relationship of antimicrobial usage to resistance in human and animal populations, emerging microbial threats, foodborne diseases, healthcare-associated infections, assessment of impact of One Health interdisciplinary intervention strategies and antimicrobial drug development incentives
My laboratory investigates the mechanisms of antibiotic resistance expressed by Neisseria gonorrhoeae with special emphasis on the role of multi-drug efflux pumps. Additional studies relate to the role of host-derived cationic antimicrobial peptides in the innate immune response to infection and how bacterial pathogens resist their action.
My areas of interest in the field of antimicrobial resistance are focused on highly drug resistant tuberculosis including multidrug resistant (MDR) - and extensively drug resistant (XDR)-TB. Other areas of interest including highly drug resistant nosocomial pathogens.
My primary role is to ensure up-to-date practices for antimicrobial resistance testing in the clinical microbiology laboratory based on current standards, evolving technologies, and emerging infectious diseases. I review test results with attention to unusually resistant isolates, patterns and trends, and identify organisms of interest for applied research projects.
We are studying the activities and macromolecular structures of 1) ribosomal RNA methyltransferases that confer bacterial resistance to antibiotics (e.g. aminoglycosides), and 2) viral and cellular non-coding RNAs that regulate proteins of the human innate immune system.
Since 1997 I have been the PI and Director of the CDC-funded Gonococcal Isolate Surveillance Project (GISP; http://www.cdc.gov/std/gisp/) Regional Laboratory in Atlanta. In that capacity I have been involved in studies of antimicrobial resistance in N. gonorrheae and have contributed data that has led to changes in the CDC guidelines for the treatment of gonorrhea.
Our research is focused on understanding how gene expression is regulated during stress and from antibiotic resistance. Specifically we study the activation of toxin-antitoxin complexes that influence biofilm formation and bacterial persistence, and from ribosomal RNA modifications that confer antibiotic resistance (in collaboration with the Conn lab).
My major laboratory research interests concern mucosal pathogenesis of Haemophilus influenzae. Experiments have focused on the mechanisms of attachment, colonization and invasion of human nasopharyngeal mucosa by H. influenzae. Current laboratory research is also focused on molecular epidemiology of invasive bacterial pathogens including H. influenzae, Streptococcus pneumoniae, and MRSA.
My research program focuses on understanding mechanisms of bacterial pathogenesis, with the goal of developing novel therapies to prevent or treat life-threating infections, particular lung infections in patients with cystic fibrosis.
I focus on two major, related areas of healthcare epidemiology related to multi drug resistant pathogens: 1) understanding the risk factors for, and outcomes of, infections caused these organisms, especially as it relates to antibiotic stewardship; and 2) preventing the transmission of these pathogens causing healthcare-associated infection, particularly environmental assessment and interventions.
My laboratory studies pathogen interactions with host. Because host molecules used by various pathogens are frequently dysregulated in cancer, we identified anti-cancer therapeutics with significant anti-pathogen activity, which are less likely to engender resistance. Recent studies in primates indicate that the cancer drug Gleevec has potent activity against tuberculosis, a result we are currently working to extend into human trials against multi-drug resistant TB.
The goal of our research is to develop protocols for the administration of antibiotics in individual and groups of patients that will maximize the rate of clearance of infections whilst minimizing the likelihood of the emergence and ascent of resistance during therapy and the spread of resistant in the community.
Dr. Lutgring is an assistant professor at Emory in the School of Medicine (Department of Medicine, Division of Infectious Diseases). In addition, he works at the Centers for Disease Control and Prevention in the Division of Healthcare Quality Promotion. His clinical and research interests are in the areas of antibiotic resistance (particularly gram-negative bacteria) and the clinical microbiology laboratory.
Clostridium difficile, or C. diff as it is commonly known, is considered an "Urgent" antibiotic resistance threat by the CDC. Our research is focused on two distinct aspects of C. difficile pathogenesis: the resistance of the bacterium to antimicrobials and the formation of dormant spores in the host.
My primary research interest is the epidemiology of antibacterial resistance, especially as it applies to the healthcare setting, and as it is affected by antimicrobial use and appropriate diagnostic testing.
As an infectious diseases clinician, I encounter antimicrobial resistance as a frequent challenge in my infected patients. As a translational researcher I conduct clinical and laboratory studies to discover and evaluate new drugs and diagnostic tests, as well as vaccines and monoclonal antibodies, to improve our ability to treat patients infected with resistant organisms.
The recipient of a public health law grant from the Robert Wood Johnson Foundation, Professor Price has published articles on law and policy relevant to control of drug-resistant tuberculosis. She also works with the U.S.-Mexico Border Health Commission's Tuberculosis Consortium.
The Quave research group investigates the anti-infective potential of botanical natural products for the treatment of multi-drug resistant pathogens. Research is focused on the discovery of bacterial pathogenesis and virulence inhibitors with the goal of developing adjuvant therapies to enhance and restore efficacy of existing lines of antibiotics.
Mechanisms of tuberculosis (TB) pathogenesis and host immunity to Mycobacterium tuberculosis (Mtb) infection in mice and humans; targeting pathogen- and host-specific factors for developing immunomodulatory therapeutics for TB and/or adjunctive therapy against drug-susceptible and drug-resistant TB.
Evaluating methods for detection of heteroresistant vancomycin intermediate Staphylococcus aureus (hVISA) and characterization of MRSA infections with reduced levels of vancomycin susceptibility.Defining the spectrum of genetic variant that cause reduced to non-susceptibility to vancomycin in S. aureus. Development of a genetic assay for vancomycin intermediate S. aureus (VISA).
The Laboratory of Biochemical Pharmacology (LOBP) has a primary research focus of drug discovery and drug development of novel antiviral agents against HIV, hepatitis B and C, Chikungunya, Ebola, Dengue, and other emerging viruses. Using high-throughput screening, we determine antiviral potency, selection for drug resistance and cytotoxicity.
My research interest is in the epidemiology and prevention of healthcare associated infections including those caused by antibiotic resistant pathogens. Recent work has focused on measurement and prevention of catheter associated bloodstream infections and the study of secular trends of infections caused by antibiotic resistant pathogens including MRSA.
Infections associated with medical devices remain a significant problem in clinical medicine. Our laboratory has been specifically interested in developing novel techniques to image bacteria in vivo and to apply these strategies for targeted delivery of antibiotics.
My laboratory investigates (1) antibiotic resistance mechanism(s) of S. pneumoniae strains, including gene transfer mechanisms, (2) global epidemiology of pneumococcal strains resistant to antibiotics, (3) the pressure of current pneumococcal vaccines on the spread of, or changes on, antibiotic resistance and (4) role of pneumococcal biofilm structures on antimicrobial resistance.